deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT03233347

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma

Sponsor: Academic and Community Cancer Research United

Conditions Ann Arbor Stage I Hodgkin Lymphoma Ann Arbor Stage IA Hodgkin Lymphoma Ann Arbor Stage IB Hodgkin Lymphoma Ann Arbor Stage II Hodgkin Lymphoma Ann Arbor Stage IIA Hodgkin Lymphoma Ann Arbor Stage IIB Hodgkin Lymphoma Classic Hodgkin Lymphoma
Interventions Brentuximab Vedotin Dacarbazine Doxorubicin Laboratory Biomarker Analysis Nivolumab Vinblastine
Updated 20 times since 2017 Last updated: Sep 30, 2025 Started: Oct 13, 2017 Primary completion: Jul 1, 2025 Completion: Jul 8, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ann Arbor Stage I Hodgkin Lymphoma and Ann Arbor Stage IA Hodgkin Lymphoma, this trial is ongoing. The trial is conducted by Academic and Community Cancer Research United and has accumulated 20 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Jun 2019 · 7 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2020 · 13 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jun 2022 · 13 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Aug 2023 · 11 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – ~Nov 2025 · 3 months · monthly snapshot~Nov 2025 – present · 10 months · monthly snapshot

Change History

20 versions recorded

  1. Nov 2025 — Present [monthly]

    Active Not Recruiting PHASE2

    Status: Unknown → Active Not Recruiting

  2. Aug 2025 — Nov 2025 [monthly]

    Unknown PHASE2

    Status: Active Not Recruiting → Unknown

  3. Sep 2024 — Aug 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Oct 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 15 earlier versions

  1. Sep 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Aug 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2022 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  5. May 2021 — Jun 2022 [monthly]

    Recruiting PHASE2

  6. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE2

  7. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  8. Jul 2019 — Aug 2020 [monthly]

    Recruiting PHASE2

  9. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  10. Nov 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

  11. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  12. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  13. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  14. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  15. Aug 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Academic and Community Cancer Research United
  • National Cancer Institute (NCI)
Data source: Academic and Community Cancer Research United

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations